Myriad Genetics Inc. is hoping to soon add prostate cancer to the growing list of indications for use of its BRACAnalysis CDx in combination with Lynparza (olaparib), following the announcement of positive results in a subset of prostate cancer patients. Astrazeneca plc and Merck & Co. reported Wednesday that their phase III PROfound study showed that men with castration-resistant prostate cancer (mCRPC) who tested positive for germline and somatic mutations in homologous recombination repair (HRR) genes responded well to the poly (ADP-ribose) polymerase (PARP) inhibitor. Based on that findings, Myriad said it will seek FDA approval of BRACAnalysis CDx as a companion diagnostic for Lynparza in men with mCRPC who have germline BRCA mutations.